Eribulin mesylate in patients with refractory cancers: a Phase I study. - sprookjes - yvandenbroek - TriplyDB

Eribulin mesylate in patients with refractory cancers: a Phase I study.

Eribulin mesylate in patients with refractory cancers: a Phase I study.

http://www.wikidata.org/entity/Q36205403

about

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide Eribulin in Cancer Treatment Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.Predicting success in regulatory approval from Phase I results.Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane Tubulin: an example of targeted chemotherapy.A Survey of Marine Natural Compounds and Their Derivatives with Anti-cancer Activity Reported in 2012.Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Eribulin in advanced liposarcoma and leiomyosarcoma.Eribulin in non-small cell lung cancer: challenges and potential strategies.Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.Eribulin shows high concentration and long retention in xenograft tumor tissues.Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.Eribulin in advanced breast cancer: safety, efficacy and new perspectives.Advances in the treatment of soft tissue sarcoma: focus on eribulin.Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.

P2860

Q26749476-93C2CA8A-C174-4520-926A-A89BBFA5294D Q26799328-B3199999-BA8F-48BA-8E5F-4E4A04C79C0F Q28078116-89A09FB4-9B80-4817-8519-1CFB75F44C4B Q28088354-111203C6-9F3A-49D1-8CA9-4642F3F4C54C Q33584160-9BB9D683-3D01-4D5C-9D51-69A79A6DD83C Q34683835-729772A1-D094-4629-B19E-1AB15B230540 Q34964991-42CA867A-2457-47B5-93BB-3A77B69AF851 Q35678690-97791356-2863-46EB-AA21-77ABDC2CB868 Q35809924-C65F92EA-8988-4B58-970F-F44BA24CC5C2 Q36181279-34F634AB-85CD-4DFC-82E6-DB9D06F0647D Q37161899-F141DE3E-E1FB-4906-88C3-294A8B2FF30B Q37177111-BB20981B-3587-439F-93E1-07E0E343A8CD Q38086872-450F59BF-61FD-4E6B-86E1-990B8E699507 Q38436152-1DA064AE-0174-494A-8FF5-AA99A15D9AB5 Q38686622-60D12B93-A736-4DA7-8885-1C2B04C5CFAE Q38688042-E826E774-1C64-4212-B3F0-EE91B3A7DA9D Q38711371-DA2B343E-C8A4-4328-8706-D0982AB771E3 Q38722807-4B646793-5470-4476-ADC9-3C75FC272970 Q39120142-D27F0120-462C-47D3-9EC2-9955B470A67D Q39288216-FC44854F-BB5D-4E5D-BAF6-CDE97E004223 Q39326914-C45D83AD-EDCA-4125-A9D0-87B1C4F32605 Q41159925-7578DCCD-D1CA-4CE6-9ABF-582BEAA92EAA Q47111016-92069F06-C927-47A0-AD99-A410D53ACC9D Q47794057-C4CACA44-6E4A-4029-8B35-5C3794B09CA3 Q49261685-0FE89A3A-1BBD-4A79-8008-B21BEAC63E35 Q51091552-E2BE5FB6-7414-462B-835E-51A387710E8D Q51301390-5B1CB6BF-CA28-4993-8AFA-2E98E82DFB7B

P2860

Eribulin mesylate in patients with refractory cancers: a Phase I study.

http://www.wikidata.org/entity/Q36205403

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@ast

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@en

type

label

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@ast

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@en

prefLabel

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@ast

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@en

P1433

Q36205403-BA50334D-68F2-491F-933E-0DE3E90B43C7

P1476

Q36205403-090368C0-3658-48D7-8E8E-B40DE4B446F5

P2093

Q36205403-173C704D-4BDD-4109-9647-797928378AFD

Q36205403-1A78CE9C-1750-482C-9EA9-BD372D4D4E97

Q36205403-792B44B0-8D1F-4603-9A3A-BC92D081B360

Q36205403-BFEE1F44-42A4-4102-9A72-227D7DF52BC7

Q36205403-F80A3F78-240E-42D1-80E9-7C155C032206

P2860

Q36205403-0D7A809D-A3D3-49BA-9F12-EECDAF3A8BF6

Q36205403-595E4CCA-B686-44B7-B590-E9EB88604F39

Q36205403-61C7EC58-AB85-4177-9B20-FFF603EF3AB9

Q36205403-65379623-F3C1-426B-8888-2B739D4452C0

Q36205403-6E849208-D02B-4172-A967-1A2CA98B920A

Q36205403-82B69526-29BF-4879-B251-AF3594CEA99B

Q36205403-9697370F-B6DB-4FC2-A8BD-C47561B52707

Q36205403-9A30155E-E08E-478E-9C91-22E2DAD20767

Q36205403-9B35A9C9-CC92-44AE-B9CA-4DBCE066F985

Q36205403-D267DE8E-DAE0-46C6-A040-DC38BC3F3C05

P2888

Q36205403-D2369FDE-D45C-45A3-9079-E47CEA4BBD87

P304

Q36205403-2440394F-DAA0-4CD7-8B2B-3FDBEF345F8A

P31

Q36205403-02BB71FB-E5C4-4A2B-8AA7-6C21F386AD75

P356

Q36205403-DE5A9E3B-31D0-4F04-8295-F4E8C2CE5223

P433

Q36205403-9DBC0FED-61D8-42F1-8298-6F4A5FB1FC40

P478

Q36205403-2534D033-23C0-4C90-9CDB-98CAC0807716

P577

Q36205403-541C4A4A-C5DA-4830-9496-5755BDBACC2B

P5875

Q36205403-5A3BD1EF-93BC-4FEF-85C5-48E34341D0DF

P698

Q36205403-81E3E7CE-7C8D-4D0A-9914-76A65980E718

P921

Q36205403-CEAFE8FA-CA04-4388-ABE3-E5BDA7B0D0A3

P932

Q36205403-177FD03F-0B00-41E1-BE81-86C1D87F6E98

P356

S10637-011-9741-2

P1433

Investigational New Drugs

P1476

Eribulin mesylate in patients with refractory cancers: a Phase I study.

@en

P2093

Hirofumi Mukai

http://www.w3.org/2001/XMLSchema#string

Hironobu Minami

http://www.w3.org/2001/XMLSchema#string

Masayuki Namiki

http://www.w3.org/2001/XMLSchema#string

Shunji Nagai

http://www.w3.org/2001/XMLSchema#string

Toru Mukohara

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Management of toxicities associated with the administration of taxanes.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

P2888

s10637-011-9741-2

P304

1926-1933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9741-2

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51615152

http://www.w3.org/2001/XMLSchema#string

P698

21887501

http://www.w3.org/2001/XMLSchema#string

P921

eribulin mesylate

P932

3432792

http://www.w3.org/2001/XMLSchema#string